Tactiva is a development stage immuno-oncology company with a unique approach to adoptive T-cell therapy. Tactiva's dual enhanced adoptive cell therapy (DEACT™) platform, consists of engineered CD4/CD8 cells which generate a durable supply of CD4 cells with direct anti-tumor activity as well as sustained helper function to CD8 T cell derived TCR-transduced effector T cells. Tactiva Therapeutics is working to develop the next generation of cancer immunotherapies by utilizing a new approach to cell therapy. This type of personalized cancer treatment enhances the patient's immune system ability to tackle the disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/03/18 | $35,000,000 | Series A |
Efung Capital Panacea Ventures Vi-Ventures | undisclosed |
